Organovo-Chat Forum: Community User: EuGeHe

😝

😂

Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Weiß jemand was los ist?

👀👀👀👀

Und wieder rückwärts 😱🙈

Weiß jemand warum es hier steigt?

Oder eine Übernahme

Irgendwann gehen die Lichter hier wohl aus

bin neu hier und wollte fragen, ob ihr abschätzen könnt, wann etwa mit relevantem umsatz gerechnet werden kann?

Wann kommt der Durchbruch

Organovo released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH). Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo, and FXR314 was also found to be safe and well tolerated. “The key findings of this study are that once daily oral FXR314 demonstrated statistically significant liver fat reduction and excellent tolerability. Whereas other FXR agonists have had challenges in providing clear benefit without significant pruritus or other adverse events, or have had lack of efficacy potentially related to lack of sustained exposure, we are pleased to note FXR314’s data demonstrate it clearly rises above previous problems seen with the class,” stated Keith Murphy, Organovo’s Executive Chairman. Organovo shares are moving on heavy trading volume following the release of Phase 2 results Monday. According to data from Benzinga Pro, more than 45 million shares have already been traded in the session, compared to the stock’s 100-day average of less than 102,000 shares.

https://www.benzinga.com/amp/content/38251203

Sowohl ald auch :D

Willst du wissen, was passiert ist oder warum es passiert ist!? 😄😄

Was ist passiert?